United States: FDA Issues Distribution Of Risk Information Draft Guidance Amid Asserted Push To Release Guidance On Manufacturer Communications

The U.S. Food and Drug Administration (FDA or the Agency) issued the June 6, 2014, draft guidance (Draft Guidance) in response to stakeholder inquiries into the Agency's views on disseminating new scientific or medical publications regarding safety information for approved drugs. In contrast to a draft guidance the Agency released in February 2014—which pertains to the distribution of publications that include information on unapproved new uses of approved drugs—the June 2014 Draft Guidance addresses how manufacturers may disseminate new risk information relating to approved uses of a prescription drug (human or animal). Specifically, the guidance is intended to address issues specific to the distribution of new information about risks that further characterizes risks discussed in the approved labeling. In this regard, the FDA acknowledges that it may be helpful for health care professionals to be apprised of "significant new risk information about an approved product in a timely manner," as drug safety assessments may "evolve throughout [the drug's] lifecycle as the extent of exposure to the product increases ...." In light of the variability in evidence and the potential for new risk information to generate confusion among providers, however, the FDA found that guidance was necessary to help ensure the appropriate distribution of such information.

Scope of the Draft Guidance

Notably, the Draft Guidance does not apply to risk information that indicates that a risk described in approved labeling is more serious than previously understood or that relates to newly identified risks. Likewise, it does not apply to medical devices. Rather, the Draft Guidance applies to "new risk information" relating to a prescription drug, defined as "information that becomes available after a drug is marketed and that rebuts or mitigates information about a risk already identified in the approved labeling or otherwise refines risk information in the approved labeling in a way that does not indicate greater seriousness of risk" (emphasis added). It should also be noted that, for purposes of the Draft Guidance, "new risk information" does not refer to "new safety information" as defined in Section 505-1(b)(3) of the Federal Food, Drug, and Cosmetic Act (the Act), and as to which the Agency has the authority to require a change in labeling as it determines appropriate.

Finally, because the Agency anticipates that new risk information largely takes the form of recently published studies rather than as textbooks or clinical practice guidelines, the recommendations in the Draft Guidance focus on the distribution of new risk information in the form of reprints and digital copies of a published study.

Parameters for Appropriate Distribution of New Risk Information

The FDA recommends that manufacturers "carefully consider the reliability and persuasiveness of" new risk information before distributing such information to health care professionals and health care entities. Accordingly, the FDA states that manufacturers should review the strength of the existing evidence that underlies the drug's approved labeling when assessing whether it would be appropriate to disseminate the new risk information.

With regard to enforcement policy, the Agency indicates that it "does not intend to object to the distribution of new risk information that rebuts, mitigates, or refines the risk information in the approved labeling" and that is in the form of a reprint or digital copy of a published study, provided that the study and manner of distribution comply with the standards set forth in the Draft Guidance. In contrast, the FDA asserts that distribution of risk information "that is not consistent with this guidance may render the labeling of a drug false and misleading" under the Act (emphasis added). As described below, the Draft Guidance articulates several criteria relating to the data sources for new risk information as well as how such information should be distributed.

New Risk Information Data Sources

  • A study or analysis should meet design and other methodologic standards accepted for a study or analysis of its type and should be adequately well-designed and informative
  • If used to rebut a prior determination that a drug may have a causal relationship with the occurrence of an adverse event, or if used to mitigate a described risk, the study or analysis should be at least as persuasive as the evidence underlying the risk assessment of causality, severity and/or incidence of the adverse reaction as reflected in the approved labeling
  • The study or analysis conclusions should constitute a fair characterization of and give appropriate weight and consideration to all relevant information (including contrary or otherwise inconsistent findings)
  • The study or analysis should be published in an independent peer-reviewed journal

Method of Distributing New Risk Information

  • When distributing any reprint or digital copy of a published study, manufacturers should include a cover sheet that contains certain information, including:

    • a description of the study, its critical findings and any significant methodologic or other limitations relevant to the persuasiveness or scope of the findings;
    • a statement that the information is inconsistent with certain risk information in the drug's approved labeling (and should specifically identify the inconsistent information);
    • a statement that the FDA has not reviewed the new risk information; and
    • any conflicts of interest (financial interests or affiliations) between the manufacturer and study author(s)
  • Manufacturers should include a copy of the approved labeling with the disseminated reprint or digital copy of the published study
  • Any promotional materials should be separated from the reprints or digital copies
  • If a representative of the manufacturer makes any statements regarding the reprint to the health care professional or health care entity recipient, such statements should be consistent with the reprint and the above-referenced cover sheet

Implications

The Draft Guidance provides some welcome clarity on a prescription drug or biological product manufacturer's ability to distribute post-market, risk-related information outside of the approved product labeling. However, the Draft Guidance includes limits on the type and content of the information to be provided, such as limiting it to information that does not rise to the level of safety information that would require a labeling change, and proscriptions on the type of data sources that may be relied upon and how they must be presented. Likewise, the Draft Guidance does not discuss how a manufacturer should assess or determine if the type or degree of post-market, risk-related information might constitute safety information that would require a labeling change.

The Draft Guidance, in addition to the February 2014 draft guidance regarding the distribution of scientific and medical publications on unapproved new uses of approved drugs or approved or cleared devices, is one of several guidance documents relating to manufacturer communications that FDA intends to issue by the end of the year. Other guidance that the FDA has stated is forthcoming includes how manufacturers should respond to unsolicited requests for information, manufacturer discussions regarding scientific information more generally and health care economic information. The Agency's effort to provide additional clarity on these topics and on its position regarding how manufacturers may permissibly discuss off-label use is part of a broader-stated commitment by the Agency to review its regulatory framework for manufacturer communications regarding medical products. It remains to be seen, however, whether such efforts and additional guidance will produce policies that more closely align with developing judicial case law on the interplay between First Amendment principles and a regulated product manufacturer's discussion of labeled and of off-label use.

Manufacturers should consider submitting comments regarding the Draft Guidance to the FDA. Any comments should be submitted by August 25, 2014, to ensure consideration by the Agency in connection its preparation of the final version of the guidance.

FDA Issues Distribution Of Risk Information Draft Guidance Amid Asserted Push To Release Guidance On Manufacturer Communications

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions